Publications and links to organisations that the GVDN is working with

Publications that GVDN partners have been involved in

Below is a selection of publications which Global Vaccine Data Network (GVDN) partners have been involved in. These publications address various aspects of vaccine safety, with a focus on collaborative observation studies that use large healthcare databases to look for rare adverse events following vaccination. The publications are presented geographically by World Health Organisation (WHO) region to demonstrate the global representation of partners in the GVDN.

World Health Organisation (WHO) Member States are grouped into six regions. Map from

African Region

Ghoor, A., Mabaso, T., Mopeli, K., Izu, A., Madhi, S. A., Lala, S. G., … & Dangor, Z. (2018). Empyema in children hospitalised at Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa: A retrospective study. South African Medical Journal, 108(12), 1055-1058. 

European Region

Andrews, N., Stowe, J., Miller, E., Svanström, H., Johansen, K., Bonhoeffer, J., & Hviid, A. (2012). A collaborative approach to investigating the risk of thrombocytopenic purpura after measles–mumps–rubella vaccination in England and Denmark. Vaccine, 30(19), 3042-3046. 

Arnheim-Dahlström L, Pasternak B, Svanström H, Sparén P, Hviid A. (2013). Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort studyBmj. 2013 Oct 9;347:f5906.

Artama M, Rinta-Kokko H, Nohynek H, Jokinen J, Palmu AA. (2018) Register-based ecologic evaluation of safety signals related to pneumococcal conjugate vaccine in children. Curr Drug Saf. 2018 Apr 6.

Bollaerts, K., Ledent, E., de Smedt, T., Weibel, D., Emborg, H. D., Danieli, G., … & Tramontan, L. (2019). ADVANCE system testing: Benefit-risk analysis of a marketed vaccine using multi-criteria decision analysis and individual-level state transition modelling. Vaccine

Dieleman, J., Romio, S., Johansen, K., Weibel, D., Bonhoeffer, J., & Sturkenboom, M. (2011). Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. Bmj, 343, d3908. 

Dodd, C., de Ridder, M., Weibel, D., Mahaux, O., Haguinet, F., de Smedt, T., … & Huerta, C. (2020). ADVANCE system testing: estimating the incidence of adverse events following pertussis vaccination in healthcare databases with incomplete exposure data. Vaccine

Edwards K, Hanquet G, Black S, Mignot E, Jankosky C, Shimabukuro T, …& Neels P. (2019). Meeting report narcolepsy and pandemic influenza vaccination: What we know and what we need to know before the next pandemic? A report from the 2nd IABS meeting. Biologicals 2019 Jul;60:1-7.

Hviid, A., Svanström, H., Scheller, N. M., Grönlund, O., Pasternak, B., & Arnheim‐Dahlström, L. (2018). Human papillomavirus vaccination of adult women and risk of autoimmune and neurological diseases. Journal of internal medicine, 283(2), 154-165. 

Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J, … & Kilpi T. (2012). AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 2012;7(3): e33536.

Romio, S., Weibel, D., Dieleman, J. P., Olberg, H. K., de Vries, C. S., Sammon, C., … & Lapeyre-Mestre, M. (2014). Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe. PloS one, 9(1). 

Scheller NM, Svanström H, Pasternak B, Arnheim-Dahlström L, Sundström K, Fink K, Hviid A. (2015). Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA. 2015 Jan 6;313(1):54-61.

Simpson C.R., Robertson C., Vasileiou E., McMenamin J., Gunson R., Ritchie L.D.,…and Sheikh A. (2020). Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II): protocol for an observational study using linked Scottish national data. BMJ Open 2020;10:e039097.

Skufca J, Ollgren J, Artama M, Ruokokoski E, Nohynek H, Palmu AA. (2018). The association of adverse events with bivalent human papilloma virus vaccination: A nationwide register-based cohort study in Finland. Vaccine. 2018 Sep 18;36(39):5926-5933.

Skufca J, Ollgren J, Ruokokoski E, Lyytikainen O, Nohynek H. (2017). Incidence rates of Guillain Barré (GBS), Chronic Fatigue/Systemic Exertion Intolerance Disease (CFS/SEID) and Postural Orthostatic Tachycardia Syndrome (POTS) prior to introduction of Human Papilloma Virus (HPV) vaccination among adolescent girls in Finland, 2002-2012. Papillomavirus Res. 2017;3:91-96.

Weibel, D., Dodd, C., Mahaux, O., Haguinet, F., De Smedt, T., Duarte-Salles, T., … & McGee, C. (2019). ADVANCE system testing: Can safety studies be conducted using electronic healthcare data? An example using pertussis vaccination. Vaccine

Region of the Americas

Baxter, R., Lewis, E., Goddard, K., Fireman, B., Bakshi, N., DeStefano, F., . . . and Klein, N. P. (2016). Acute demyelinating events following vaccines: a case-centered analysis. Clinical Infectious Diseases, 63(11), 1456-1462.

DeSilva, M., Vazquez-Benitez, G., Nordin, J. D., Lipkind, H. S., Romitti, P. A., DeStefano, F., & Kharbanda, E. O. (2016). Tdap vaccination during pregnancy and microcephaly and other structural birth defects in offspring. Journal of the American Medical Association, 316(17), 1823-1825.

Greene, S. K., Rett, M. D., Vellozzi, C., Li, L., Kulldorff, M., Marcy, S. M., … & Jackson, M. L. (2013). Guillain-Barré syndrome, influenza vaccination, and antecedent respiratory and gastrointestinal infections: a case-centered analysis in the Vaccine Safety Datalink, 2009–2011. PLoS One, 8(6).

McNeil, M. M., Gee, J., Weintraub, E. S., Belongia, E. A., Lee, G. M., Glanz, J. M., … & Jackson, L. A. (2014). The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety. Vaccine, 32(42), 5390-5398.

South-East Asia Region

Wahl, B., Sharan, A., Knoll, M., Kumar, R., Liu, L., Chu, Y., … & Arora, N. (2019). National, regional, and state-level burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in India: modelled estimates for 2000–15. The Lancet Global Health, 7(6), e735-e747.

Western Pacific Region

Griffin, J. B., Yu, L., Watson, D., Turner, N., Walls, T., Howe, A. S., … & Petousis-Harris, H. (2018). Pertussis Immunisation in Pregnancy Safety (PIPS) Study: A retrospective cohort study of safety outcomes in pregnant women vaccinated with Tdap vaccine. Vaccine, 36(34), 5173-5179.

Liu, C., Yeh, Y., Huang, W., Chie, W. & Chan, A. (2020). Assessment of pre-specified adverse events following varicella vaccine: A population-based self-controlled risk interval study. Vaccine, 38(11), 2495-2502.

Huang, W., Juan, Y., Liu, C., Yang, Y. & Chan, K. (2020). Intussusception and Kawasaki disease after rotavirus vaccination in Taiwanese infants. Vaccine, 38(40) 6299-6303.

Petousis-Harris, H., Jiang, Y., Yu, L., Watson, D., Walls, T., Turner, N., … & Griffin, J. B. (2019). A Retrospective Cohort Study of Safety Outcomes in New Zealand Infants Exposed to Tdap Vaccine in Utero. Vaccines, 7(4), 147.


Black, S. B., Law, B., Chen, R.T., Dekker, C.L., Sturkenboom, M., Huang, W-T., Gurwith, M., and Poland, G. (2021). The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety. Vaccine 2021 March 6.

Dodd, C. N., Romio, S. A., Black, S., Vellozzi, C., Andrews, N., Sturkenboom, M., … & Crawford, N. (2013). International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines. Vaccine, 31(40), 4448-4458.

Guillard-Maure, C., Elango, V., Black, S., Perez-Vilar, S., Castro, J. L., Bravo-Alcántara, P., … & Kuli-Lito, G. (2018). Operational lessons learned in conducting a multi-country collaboration for vaccine safety signal verification and hypothesis testing: The global vaccine safety multi country collaboration initiative. Vaccine, 36(3), 355-362.

Perez-Vilar, S., Weibel, D., Sturkenboom, M., Black, S., Maure, C., Castro, J. L., … & Nakato, S. (2018). Enhancing global vaccine pharmacovigilance: Proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination. Vaccine, 36(3), 347-354.

Petousis-Harris H. (2020). Assessing the Safety of COVID-19 Vaccines: A Primer. Drug Safety.

Petousis-Harris H. and Dodd CN. (2020). Progress Toward a Global Vaccine Data NetworkThe Pediatric Infectious Disease Journal. 2020 Jun 3.

Weibel, D., Sturkenboom, M., Black, S., de Ridder, M., Dodd, C., Bonhoeffer, J., … & Gentile, A. (2018). Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines–Multi-country assessment. Vaccine, 36(41), 6202-6211.

Links to organisations that the GVDN is working with on vaccine safety and effectiveness

Brighton Collaboration
The Brighton Collaboration is committed to making reliable information available so that vaccine recipients and decision makers can evaluate vaccine benefits and risks accurately.

Children’s Hospital of Philadelphia
For thorough and authoritative information about vaccine safety, including the immune system, different vaccine examples, vaccine doses and ingredients, and chronic conditions that some people link to vaccination.

Coalition for Epidemic Preparedness Innovations
The Coalition for Epidemic Preparedness Innovations (CEPI) is a foundation that finances independent research projects to develop vaccines against emerging infectious diseases.

The COVID-19 Global Vaccine Access Facility (Covax Facility) will provide vital seed funding to the Gavi Advance Market Commitment for COVID-19 Vaccines (Gavi Covax AMC) to support high-risk populations in low-income countries (LICs) and lower middle-income countries (LMICs). It aims to pool resources and share vaccine development risk. (LMICs).

GAVI, officially Gavi, the Vaccine Alliance is a public–private global health partnership with the goal of increasing access to immunisation in poor countries Gavi has helped vaccinate more than 760 million children in the world’s poorest countries, preventing more than 13 million deaths, as part of its mission to save lives, reduce poverty and protect the world against the threat of epidemics.

Johns Hopkins University’s Coronavirus Resource Centre
The COVID-19 Global Map was developed by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Johns Hopkins experts in global public health, infectious disease, and emergency preparedness have been at the forefront of the international response to COVID-19. The Coronavirus Resource Centre’s website is a resource to help advance the understanding of the virus, inform the public, and brief policymakers in order to guide a response, improve care, and save lives.

World Health Organisation / Immunisation
The World Health Organization (WHO) is a specialized agency of the United Nations responsible for international public health. Among other things, it works to ensure that every person is protected from vaccine-preventable diseases.

Print Friendly, PDF & Email